Amgen (AMGN)

This top dividend ETF is still a reliable long-term income investment.

They are fairly risky, but their potential upside is massive.

Most people don't have $12.5 billion to buy the L.A. Lakers. But with stock ETFs, you could earn a higher return than the Lakers' owners.

They are way more than just GLP-1 stocks.

Retail sales just fell for the first time in nine months, and consumer confidence dropped to 51. Here's what a tired shopper means for the stock market.

Revenue surged 10% as six growth drivers now fuel 70% of product sales.

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.65% on an annualized basis producing an average annual return of 14.88%. Currently, Amgen has a market capitalization of $223.91 billion.

Amgen’s second quarter results reflected broad-based portfolio momentum, with management crediting double-digit growth in key products like Repatha, EVENITY,...

Berobenatide is one of the keys to Pfizer's future.

What Happened? Shares of biotech company Amgen (NASDAQ:AMGN) jumped 3.1% in the afternoon session after the company reported strong second-quarter 2026 finan...